{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:48:29Z","timestamp":1791996509030,"version":"4.4.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.bone.2016.02.019","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T22:36:28Z","timestamp":1457044588000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["The effects of proteasome inhibitors on bone remodeling in multiple myeloma"],"prefix":"10.1016","volume":"86","author":[{"given":"Maurizio","family":"Zangari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Suva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2016.02.019_bb0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bone.2016.02.019_bb0010","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ctrv.2011.12.007","article-title":"Impact of bortezomib on bone health in myeloma: a review of current evidence","volume":"38","author":"Zangari","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bone.2016.02.019_bb0015","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma","volume":"17","author":"Raje","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2016.02.019_bb0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2016.02.019_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-9966-27-11","article-title":"Effect of pathologic fractures on survival in multiple myeloma patients: a case control study","volume":"27","author":"Sonmez","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bone.2016.02.019_bb0030","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2016.02.019_bb0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bone.2016.02.019_bb0040","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/cncr.22678","article-title":"Economic burden of metastatic bone disease in the U.S.","volume":"109","author":"Schulman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2016.02.019_bb0045","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2016.02.019_bb0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1517\/14712598.2015.978853","article-title":"Treatment of multiple myeloma bone disease: experimental and clinical data","volume":"15","author":"Papamerkouriou","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bone.2016.02.019_bb0055","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0060","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2016.02.019_bb0065","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2005.05.098","article-title":"Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function","volume":"333","author":"Zavrski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2016.02.019_bb0070","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.28481","article-title":"The effects of bortezomib on bone disease in patients with multiple myeloma","volume":"120","author":"Mohty","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2016.02.019_bb0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.seminhematol.2012.04.011","article-title":"Proteasome inhibitors and bone disease","volume":"49","author":"Qiang","year":"2012","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.21324","article-title":"Effects of bortezomib on bone disease in multiple myeloma","volume":"84","author":"Drake","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0085","first-page":"462","article-title":"Bone building with bortezomib","volume":"118","author":"Roodman","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2016.02.019_bb0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1196\/annals.1365.035","article-title":"Bone remodeling","volume":"1092","author":"Hadjidakis","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bone.2016.02.019_bb0095","doi-asserted-by":"crossref","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","article-title":"Cellular and molecular mechanisms of bone remodeling","volume":"285","author":"Raggatt","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.02.019_bb0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/CGM.S16817","article-title":"Bone disease in multiple myeloma: pathophysiology and management","volume":"7","author":"Hameed","year":"2014","journal-title":"Cancer Growth Metastasis"},{"key":"10.1016\/j.bone.2016.02.019_bb0105","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation","volume":"17","author":"Xiong","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2016.02.019_bb0110","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2016.02.019_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bone.2016.02.019_bb0120","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/er.2012-1026","article-title":"The osteocyte: an endocrine cell and more","volume":"34","author":"Dallas","year":"2013","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2016.02.019_bb0125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/bonekey.2013.129","article-title":"Effects of proteasome inhibitors on bone cancer","volume":"2","author":"Terpos","year":"2013","journal-title":"Bonekey Rep."},{"key":"10.1016\/j.bone.2016.02.019_bb0130","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0135","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jbmr.2022","article-title":"PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression","volume":"29","author":"Cafforio","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.02.019_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/bbrc.2000.2075","article-title":"Activin A is an essential cofactor for osteoclast induction","volume":"268","author":"Fuller","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2016.02.019_bb0150","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1172\/JCI116179","article-title":"Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors","volume":"91","author":"Tanaka","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2016.02.019_bb0160","doi-asserted-by":"crossref","first-page":"26656","DOI":"10.1074\/jbc.M705064200","article-title":"EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases","volume":"282","author":"Zhu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.02.019_bb0165","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2016.02.019_bb0170","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","article-title":"TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand","volume":"106","author":"Lam","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2016.02.019_bb0175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.191.2.275","article-title":"Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL\u2013RANK interaction","volume":"191","author":"Kobayashi","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bone.2016.02.019_bb0180","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.37","article-title":"Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model","volume":"4","author":"Schwarzer","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bone.2016.02.019_bb0190","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0195","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2014-12-613968","article-title":"Myeloma cell-derived Runx2 promotes myeloma progression in bone","volume":"125","author":"Trotter","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0200","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2016.02.019_bb0205","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0210","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bone.2016.02.019_bb0215","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/dvdy.20603","article-title":"Buried alive: how osteoblasts become osteocytes","volume":"235","author":"Franz-Odendaal","year":"2006","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.bone.2016.02.019_bb0225","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2016.02.019_bb0230","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","article-title":"Role of osteocytes in multiple myeloma bone disease","volume":"8","author":"Delgado-Calle","year":"2014","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.bone.2016.02.019_bb0235","doi-asserted-by":"crossref","first-page":"23084","DOI":"10.1074\/jbc.M709848200","article-title":"Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins","volume":"283","author":"Guo","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.02.019_bb0240","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2007-03-082941","article-title":"The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon-beta-induced inhibitory signaling","volume":"111","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0245","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1128\/MCB.02214-05","article-title":"The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling","volume":"26","author":"Zhao","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bone.2016.02.019_bb0250","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","article-title":"Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling","volume":"113","author":"Qiang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0255","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2141.2007.06829.x","article-title":"Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease","volume":"139","author":"Oyajobi","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0260","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jcp.21787","article-title":"Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades","volume":"220","author":"Ang","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bone.2016.02.019_bb0265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2016.02.019_bb0270","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.leukres.2008.07.028","article-title":"Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6","volume":"33","author":"Hongming","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bone.2016.02.019_bb0275","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2016.02.019_bb0280","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","article-title":"Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma","volume":"69","author":"Deleu","year":"2009","journal-title":"Cancer Res."},{"issue":"s1","key":"10.1016\/j.bone.2016.02.019_bb0285","article-title":"Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma","volume":"99","author":"Toscani","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2016.02.019_bb0290","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.leukres.2009.07.017","article-title":"Constitutive down-regulation of osterix in osteoblasts from myeloma patients: in vitro effect of bortezomib and lenalidomide","volume":"34","author":"De Matteo","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bone.2016.02.019_bb0295","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0300","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2016.02.019_bb0305","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/ejh.12069","article-title":"The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling","volume":"90","author":"Kaiser","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0310","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1600-0609.2010.01435.x","article-title":"The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells","volume":"85","author":"Eda","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0315","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbrc.2014.04.044","article-title":"Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues","volume":"447","author":"Sanvoranart","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2016.02.019_bb0320","doi-asserted-by":"crossref","first-page":"27939","DOI":"10.1074\/jbc.M304132200","article-title":"E3 ubiquitin ligase smurf1 mediates core-binding factor \u03b11\/Runx2 degradation and plays a specific role in osteoblast differentiation","volume":"278","author":"Zhao","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.02.019_bb0325","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0330","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01599.x","article-title":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma","volume":"86","author":"Delforge","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0335","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.4073.4073","article-title":"Phase I exploratory study of IV formulation of panobinostat in combination with bortezomib in relapsed\/refractory multiple myeloma patients: effect on serum PTH and gene expression profiling (GEP) studies","volume":"120","author":"Zangari","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0340","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3324\/haematol.2010.031302","article-title":"A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients","volume":"96","author":"Zangari","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2016.02.019_bb0345","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0350","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0609.2008.01164.x","article-title":"Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment","volume":"82","author":"Heider","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0355","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bone.2013.12.025","article-title":"Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors","volume":"61","author":"Zangari","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.02.019_bb0365","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0370","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3409.3409","article-title":"Higher expressions of PTH receptor type 1 and\/or 2 in bone marrow is associated to longer survival in newly diagnosed myeloma patients enrolled in total therapy 3","volume":"124","author":"Zangari","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0375","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1210\/jc.2013-2020","article-title":"Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial","volume":"98","author":"Bonnick","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.02.019_bb0380","article-title":"Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis","author":"Duong","year":"2015","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2016.02.019_bb0385","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2010.01485.x","article-title":"First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro","volume":"85","author":"Lund","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0390","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdq259","article-title":"Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid","volume":"21","author":"Terpos","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2016.02.019_bb0395","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/ijh.14.38","article-title":"Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study","volume":"3","author":"T'Seyen","year":"2014","journal-title":"Int. J. Hematol. Oncol."},{"key":"10.1016\/j.bone.2016.02.019_bb0400","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/leu.2013.267","article-title":"VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT","volume":"28","author":"Terpos","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2016.02.019_bb0405","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2016.02.019_bb0410","article-title":"Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma","volume":"8","author":"Hu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2016.02.019_bb0415","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.leukres.2014.05.022","article-title":"Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro","volume":"38","author":"Li","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bone.2016.02.019_bb0420","doi-asserted-by":"crossref","first-page":"16918","DOI":"10.1074\/jbc.M115.663963","article-title":"The proteasome inhibitor carfilzomib suppresses parathyroid hormone-induced osteoclastogenesis through a RANKL-mediated signaling pathway","volume":"290","author":"Yang","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.02.019_bb0425","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/leu.2014.69","article-title":"A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity","volume":"28","author":"Eda","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2016.02.019_bb0430","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1600-0609.2011.01602.x","article-title":"Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients","volume":"86","author":"Zangari","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2016.02.019_bb0435","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-13-1657","article-title":"Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease","volume":"20","author":"Garcia-Gomez","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2016.02.019_bb0440","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib","volume":"111","author":"Piva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bone.2016.02.019_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph8010001","article-title":"Clinical use of proteasome inhibitors in the treatment of multiple myeloma","volume":"8","author":"Merin","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bone.2016.02.019_bb0450","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2016.02.019_bb0455","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1016\/j.bmcl.2013.09.043","article-title":"Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma","volume":"23","author":"Agyin","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216300539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216300539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T19:27:16Z","timestamp":1718393236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216300539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":91,"alternative-id":["S8756328216300539"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.02.019","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of proteasome inhibitors on bone remodeling in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}